Navigation Links
A transcription factor called SLUG helps determines type of breast cancer
Date:5/2/2014

the formation of breast tumors. Because SLUG can regulate breast-cell differentiation, Kuperwasser's team investigated SLUG's role in breast-cell differentiation and tumor growth.

How the Study Was Conducted: The research team reduced the expression of the SLUG gene in human-derived breast cells and then used cell-sorting techniques to separate the cells into groups of luminal, basal, and stem cells. Next, they used mathematical modeling to measure the rate and frequency that each of the three cell types changed into another cell type. By comparing the rates between control cells and cells in which SLUG was reduced, the team was able to determine the role of SLUG in luminal-, basal-, and stem-cell transitions.

To test the result of their mathematical model, the research team examined and compared breast-tissue samples from mice in two groups: a control group with normal SLUG and an experimental group that did not express SLUG. Mammary glands from the experimental and control groups were analyzed for changes in structure, the amount and distribution of luminal and basal cells in the gland, and whether these cells had stem-cell activity.

Results: The SLUG-deficient mice exhibited defects in breast-cell differentiation. The mammary glands of these mice had too many luminal cells and defective basal cells that had luminal-cell characteristics. The control group of normal mice had a normal ratio of luminal to basal cells.

The SLUG-deficient mice showed defects in stem-cell function: Specifically, tumor formation and tissue regeneration was inhibited, an indication of defective stem cells, suggesting that SLUG was necessary to maintain normal luminal and basal cells within the mammary gland.

Additionally, SLUG-deficient cells when transplanted could not regenerate the mammary gland of the mouse, suggesting that SLUG is necessary for mammary stem-cell function. Tumor formation was also inhibited in SLUG-deficient mice
'/>"/>

Contact: Siobhan Gallagher
siobhan.gallagher@tufts.edu
617-636-6586
Tufts University, Health Sciences Campus
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Study demonstrates cells can acquire new functions through transcriptional regulatory network
2. Transcription factor Lyl-1 critical in producing early T-cell progenitors
3. NIH backs Rice University study of delay in gene transcription networks
4. Stay-at-home transcription factor prevents neurodegeneration
5. FASEB SRC announces: Mechanism and Regulation of Prokaryotic Transcription Conference
6. Transcription factor may protect against hepatic injury caused by hepatitis C and alcohol
7. System-wide analyses have underestimated the importance of transcription in animals
8. Environmental factors in Tiny Tims near fatal illness
9. Soy-based S-equol supplement reduces metabolic syndrome risk factors
10. From scourge to saint: E. coli bacteria becomes a factory - to make cheaper, faster pharmaceuticals
11. Impaired recovery of Atlantic cod -- forage fish or other factors?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/11/2015)... , May 11, 2015 Curemark LLC, ... the start of a new Phase III double blind, ... its novel formulation, CM-AT, on all children ages 3-8 ... its FDA Phase III double blinded clinical trial for ... low levels of the digestive enzyme chymotrypsin. This new ...
(Date:5/6/2015)... Israel , May 6, 2015 LifeBEAM, ... most established helmet producer, announced today that they will ... Helmet, the world,s first bio-sensing cycling helmet and the ... released in two new colors in order to give ... the product. In addition, LifeBEAM and Lazer announced their ...
(Date:4/27/2015)... 27, 2015 Profile Solutions, Inc. (OTC: PSIQ), ... systems is pleased to announce that Dr Gerry ... and member of its scientific advisory board. ... a thought leader in technology-enhanced learning models. He was ... has published studies and books focused on online student ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4
... is used to soothe every kind of pain, from simple ... is one of the most used nowadays. However, research carried ... University of Granada showed that taking paracetamol slows ... studies. Author of this work is Olga Garca Mart ...
... VIEW, Calif., Aug. 13 LaserCard,Corporation (Nasdaq: ... credentials,used in biometric identification, today announced the expansion ... Eastern government. A new centralized high-volume card ... optical memory and the eye-readable data of,this state-of-the-art ...
... deepens customer relationships, WALL, N.J., Aug. 15 ... leader in wireless public safety and,finger-based biometric identification ... quarter ended June 30, 2007. Total revenue ... 30, 2007 decreased 19% to $2.5 million from ...
Cached Biology News:Paracetamol, one of most used analgesics, could slow down bone growth 2LaserCard Corporation Announces Expansion of Middle East Project 2LaserCard Corporation Announces Expansion of Middle East Project 3BIO-key Reports Second Quarter 2007 Results 2BIO-key Reports Second Quarter 2007 Results 3BIO-key Reports Second Quarter 2007 Results 4BIO-key Reports Second Quarter 2007 Results 5
(Date:5/30/2015)... RARITAN, N.J. , May 30, 2015 ... single-arm Phase 2 MMY2002 (SIRIUS) trial show treatment ... monoclonal antibody – achieved an overall response rate ... assessed by an independent review committee, in heavily ... consistent among the pre-specified subgroups based on age, ...
(Date:5/29/2015)... Los Gatos, CA (PRWEB) May 29, 2015 ... diagnostics company addressing multi-drug-resistant organisms (MDROs), announced that ... technology for same-shift bacterial detection and susceptibility testing ... asm2015 on May 31, 2015 in ... a new class of molecular diagnostics that can ...
(Date:5/29/2015)... Columbia, Pa. (PRWEB) May 29, 2015 ... Thermal Product Solutions with a request to design ... remove excess moisture from prescription medications being produced ... custom solution that includes a robotic gantry, heat-saving ... positions and dries trays of 3D-printed pills to ...
(Date:5/29/2015)... Results from a Phase III clinical trial examining ... reduce the size of melanoma tumors in patients injected ... of Clinical Oncology. , The global, randomized trial ... melanoma, a potentially fatal form of skin cancer. The ... safety and efficacy of the oncolytic virus immunotherapy compared ...
Breaking Biology Technology:Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 2Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 3Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 4Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 5Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 6Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 7Data Highlighting GeneWEAVE’s Smarticles™ Technology to be Presented at the 115th General Meeting of the American Society for Microbiology (asm2015) 2Data Highlighting GeneWEAVE’s Smarticles™ Technology to be Presented at the 115th General Meeting of the American Society for Microbiology (asm2015) 3New industrial oven with “pill pushing” robotic gantry precisely removes excess moisture from 3D-printed pharmaceuticals 2Study Published in Journal of Clinical Oncology Reports Talimogene Laherparepvec Improvesdurable Responses in Patients with Advanced Melanoma 2
... ("Phosphagenics") (ASX: POH, AIM: PSG, OTCQX: PPGNY) today,announced ... that showed its,delivery technology, TPM, delivered leading pain-relief ... irritation of any kind., These results support ... a sustained release oxycodone patch for the management ...
... 17 /PRNewswire-FirstCall/ - Vasogen Inc.,(NASDAQ: VSGN ; ... a,leading European pharmaceutical and medical devices company, ... Vasogen,s Celacade(TM) System,in Germany. Celacade, a first-in-class ... that specifically targets the destructive chronic,inflammation underlying ...
... SGX Pharmaceuticals, Inc.,(Nasdaq: SGXP ) today announced ... Board of Directors. Mr. Turner brings over 25 years ... serve on,the company,s audit committee., "We are delighted ... S.,Henney, Chairman of the Board of Directors of SGX. ...
Cached Biology Technology:Phosphagenics Announces Successful Phase 1 Transdermal Oxycodone Clinical Trial Results 2Phosphagenics Announces Successful Phase 1 Transdermal Oxycodone Clinical Trial Results 3Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure 2Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure 3Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure 4Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure 5SGX Pharmaceuticals Appoints Joseph L. Turner to Board of Directors 2SGX Pharmaceuticals Appoints Joseph L. Turner to Board of Directors 3